|Bid||10.15 x 2900|
|Ask||10.63 x 900|
|Day's Range||10.17 - 10.54|
|52 Week Range||4.26 - 13.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 27, 2017 - May 1, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.00|
ImmunoGen, Inc., , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer today announced positive data from the FORWARD II trial evaluating mirvetuximab soravtansine in multiple combination cohorts in patients with folate receptor alpha -positive ovarian cancer.
ImmunoGen (IMGN) reports wider-than-expected loss in Q1. Lower license and milestone fees resulted in substantial decrease in year-over-revenues.
ImmunoGen posted wider-than-expected loss in the first quarter of 2018. However, revenues surpassed estimates but decreased year over year.
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 30 cents. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today reviewed recent progress in the business and reported operating results for the quarter ended March 31, 2018.
NEW YORK, NY / ACCESSWIRE / May 4, 2018 / ImmunoGen, Inc. (NASDAQ: IMGN ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 4, 2018 at 8:00 AM Eastern Time. To listen ...
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company’s lead product candidate, mirvetuximab soravtansine, is in the Phase 3 FORWARD I trial for FRα-positive platinum-resistant ovarian cancer, and is in the Phase 1b/2 FORWARD II trial in combination regimens for earlier-stage disease.
ImmunoGen's (IMGN) considerable progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the stock in Q1.
ImmunoGen, Inc. (NASDAQ:IMGN) is attracting a substantial amount of attention in the biotechnology space as we head into the close of this week, with the company putting out a release outlining some progress for its lead investigative trial. On the back of the news, Immunogen shares are seeing plenty of movement, with the implications of […] The post Here’s Why The Immunogen News Is Important For The Company appeared first on Market Exclusive.
The decision follows a recommendation by the Independent Data Monitoring Committee (IDMC) based upon successful completion of a pre-specified interim futility analysis after 80 progression-free survival (PFS) events as determined by blinded, independent central review. ImmunoGen has also completed full enrollment of the trial two months ahead of schedule and expects top-line results from FORWARD I during the first half of 2019. “Ovarian cancer is the leading cause of death from gynecological cancers, and patients diagnosed with this life-threatening disease have limited treatment options, especially once they develop platinum-resistant disease,” said Anna Berkenblit, M.D., vice president and chief medical officer of ImmunoGen.
“As ImmunoGen continues to evolve, we look to complement our existing team with outside talent with experience to accelerate our transition to a fully-integrated biotechnology company delivering innovative products to improve outcomes for cancer patients,” said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer.
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
ImmunoGen's (IMGN) shares shoot up more than 150% in a year's time on rapid pipeline progress, positive study data and strategic collaborations.
Biotech stocks continued to be in the red this week, with the losses worse than what the broader market suffered. Here's a list of key events associated with biotech stocks one needs to focus on, in the ...
Investors were generally pleased with a data drop over the weekend, but it wasn't enough to keep ImmunoGen from tanking for no apparent reason on Tuesday.
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced encouraging efficacy and favorable tolerability data from the FORWARD II cohort assessing mirvetuximab soravtansine in combination with Merck’s anti-PD-1 therapy pembrolizumab in patients with platinum-resistant epithelial ovarian cancer .
Investors in ImmunoGen (IMGN) need to pay close attention to the stock based on moves in the options market lately.
The volatile nature of biotech stocks is evident from the wild swings they experience in the wake of catalytic events, which in fact present profit-making opportunities for an astute investor. This week ...
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that three posters highlighting the Company’s expertise in ADCs will be presented at the upcoming American Association of Cancer Research Annual Meeting to be held from April 14-18, 2018 in Chicago.